Soleno Therapeutics Downgraded to 'Hold' by Cantor Fitzgerald

Analysts cut price target from $123 to $53 on the biopharmaceutical company's stock.

Apr. 9, 2026 at 6:52am

Got story updates? Submit your updates here. ›

A highly detailed, macro-level view of gears, levers, and other heavy industrial banking equipment, conveying a sense of the complex, mechanical nature of financial markets and institutions.An extreme close-up of the complex inner workings of the financial industry highlights the institutional challenges facing a biotech company's stock price.Redwood City Today

Cantor Fitzgerald has downgraded shares of Soleno Therapeutics (NASDAQ:SLNO) from an 'overweight' rating to a 'hold' rating, lowering the price target from $123 to $53. The move comes as several other equity research analysts have also recently commented on the company, with some cutting their price targets and ratings.

Why it matters

Soleno Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for rare and orphan diseases, with its lead candidate DCCR being investigated for Prader-Willi syndrome. The downgrade and price target cut by a major analyst firm could impact investor sentiment and the company's ability to raise capital or attract partnerships.

The details

In the report, Cantor Fitzgerald cited a number of factors for the downgrade, including decreased price targets from other analysts such as Wells Fargo and HC Wainwright. The analysts also noted that Wall Street Zen had cut its rating on Soleno Therapeutics from 'buy' to 'hold'. Overall, the analyst consensus on the stock has shifted from mostly positive to a 'hold' rating, with an average target price of $89.20.

  • Cantor Fitzgerald issued the downgrade report on Monday, April 9, 2026.
  • Wells Fargo decreased its price target on Soleno Therapeutics on February 27, 2026.
  • HC Wainwright reduced its price target on the company on March 4, 2026.
  • Wall Street Zen cut its rating on Soleno Therapeutics to 'hold' on March 22, 2026.

The players

Cantor Fitzgerald

A global financial services firm that provides investment banking, asset management, and other financial services.

Soleno Therapeutics

A clinical-stage biopharmaceutical company focused on developing treatments for rare and orphan diseases, including its lead candidate DCCR for Prader-Willi syndrome.

Wells Fargo

A major American multinational financial services company.

HC Wainwright

An investment banking firm that provides research, sales, trading, and banking services.

Wall Street Zen

An equity research firm that provides analysis and ratings on publicly traded companies.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching to see if Soleno Therapeutics can regain analyst confidence and a more positive rating outlook in the coming months.

The takeaway

The downgrade and price target cuts by major analysts highlight the challenges Soleno Therapeutics faces in advancing its pipeline of rare disease treatments. The company will need to demonstrate strong clinical data and commercial potential to win back investor and analyst support.